OBD vs. DDDD, TRX, FUM, OKYO, SAR, AOR, OPTI, POLB, IMM, and AREC
Should you be buying Oxford BioDynamics stock or one of its competitors? The main competitors of Oxford BioDynamics include 4D pharma (DDDD), Tissue Regenix Group (TRX), Futura Medical (FUM), OKYO Pharma (OKYO), Sareum (SAR), AorTech International (AOR), OptiBiotix Health (OPTI), Poolbeg Pharma (POLB), ImmuPharma (IMM), and Arecor Therapeutics (AREC). These companies are all part of the "biotechnology" industry.
Oxford BioDynamics vs.
Oxford BioDynamics (LON:OBD) and 4D pharma (LON:DDDD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, community ranking, institutional ownership, profitability and dividends.
4D pharma has lower revenue, but higher earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, 4D pharma had 1 more articles in the media than Oxford BioDynamics. MarketBeat recorded 1 mentions for 4D pharma and 0 mentions for Oxford BioDynamics. Oxford BioDynamics' average media sentiment score of 0.00 equaled 4D pharma'saverage media sentiment score.
Oxford BioDynamics has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, 4D pharma has a beta of 2.63, meaning that its share price is 163% more volatile than the S&P 500.
Oxford BioDynamics received 62 more outperform votes than 4D pharma when rated by MarketBeat users. However, 71.19% of users gave 4D pharma an outperform vote while only 60.47% of users gave Oxford BioDynamics an outperform vote.
4D pharma has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -1,800.32%. 4D pharma's return on equity of -89.48% beat Oxford BioDynamics' return on equity.
44.3% of Oxford BioDynamics shares are owned by institutional investors. Comparatively, 26.8% of 4D pharma shares are owned by institutional investors. 16.8% of Oxford BioDynamics shares are owned by company insiders. Comparatively, 12.2% of 4D pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
4D pharma beats Oxford BioDynamics on 7 of the 13 factors compared between the two stocks.
Get Oxford BioDynamics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oxford BioDynamics Competitors List
Related Companies and Tools
This page (LON:OBD) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy OBD Stock Free OBD Stock Alerts